AstraZeneca (MEX:AZN1N) Cyclically Adjusted Revenue per Share: MXN546.26 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:AZN1N AstraZeneca PLC MEX:AZN1N
84 GF Score
Price MXN2,777.00
GF Value MXN3,041.58
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is AstraZeneca Cyclically Adjusted Revenue per Share?

AstraZeneca MEX:AZN1N 84 Cyclically Adjusted Revenue per Share is MXN546.26 as of Jun. 2026. GuruFocus rates MEX:AZN1N with a GF Score™ of 84/100 and a GF Value™ of MXN3,041.58 (Fairly Valued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

AstraZeneca's adjusted revenue per share for the three months ended in Jun. 2026 was MXN172.074. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN546.26 for the trailing ten years ended in Jun. 2026.

During the past 12 months, AstraZeneca's average Cyclically Adjusted Revenue Growth Rate was 8.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.90% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 4.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of AstraZeneca was 9.90% per year. The lowest was -0.20% per year. And the median was 5.30% per year.

As of today (2026-09-14), AstraZeneca's current stock price is MXN2777.00. AstraZeneca's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was MXN546.26. AstraZeneca's Cyclically Adjusted PS Ratio of today is 5.08.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AstraZeneca was 6.86. The lowest was 2.82. And the median was 5.33.


AstraZeneca  (MEX:AZN1N) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

AstraZeneca's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=2777.00/546.26
=5.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AstraZeneca was 6.86. The lowest was 2.82. And the median was 5.33.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


AstraZeneca Cyclically Adjusted Revenue per Share Related Terms


AstraZeneca Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for AstraZeneca's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca Cyclically Adjusted Revenue per Share Chart

AstraZeneca Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 368.76 397.66 607.32 540.03

AstraZeneca Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 600.83 547.76 540.03 515.05 546.26

MEX:AZN1N vs LLY, JNJ, ABBV: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, AstraZeneca's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Cyclically Adjusted PS Ratio falls into.


MEX:AZN1N
84GF Score
AstraZeneca PLC MEX:AZN1N
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AstraZeneca Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AstraZeneca's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=172.074/142.3000*142.3000
=172.074

Current CPI (Jun. 2026) = 142.3000.

AstraZeneca Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 87.040 101.500 122.028
201612 90.953 102.200 126.640
201703 80.388 102.700 111.385
201706 72.118 103.500 99.154
201709 89.265 104.300 121.787
201712 89.337 105.000 121.073
201803 74.248 105.100 100.528
201806 79.947 105.900 107.426
201809 78.836 106.600 105.238
201812 99.446 107.100 132.130
201903 84.002 107.000 111.715
201906 85.254 107.900 112.434
201909 96.393 108.400 126.538
201912 95.722 108.500 125.541
202003 113.472 108.600 148.684
202006 110.312 108.800 144.278
202009 110.758 109.200 144.330
202012 112.262 109.400 146.023
202103 113.441 109.700 147.153
202106 124.148 111.400 158.584
202109 135.605 112.400 171.678
202112 157.742 114.700 195.699
202203 145.283 116.500 177.457
202206 138.904 120.500 164.034
202209 141.695 122.300 164.867
202212 140.059 125.300 159.061
202303 125.701 126.800 141.067
202306 125.458 129.400 137.965
202309 128.319 130.100 140.352
202312 130.748 130.500 142.570
202403 134.887 131.600 145.854
202406 151.939 133.000 162.563
202409 170.998 133.500 182.270
202412 198.823 135.100 209.419
202503 178.082 136.100 186.194
202506 174.608 138.400 179.528
202509 178.518 138.900 182.888
202512 178.594 139.900 181.658
202603 176.607 140.800 178.488
202606 172.074 142.300 172.074

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN546.26 mean?
AstraZeneca (MEX:AZN1N) has a Cyclically Adjusted Revenue per Share of MXN546.26 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on AstraZeneca and its competitors.
Is AstraZeneca's Cyclically Adjusted Revenue per Share too high?
AstraZeneca's current Cyclically Adjusted Revenue per Share is MXN546.26. Overall, AstraZeneca has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca's Cyclically Adjusted Revenue per Share compare to LLY and JNJ?
AstraZeneca's Cyclically Adjusted Revenue per Share of MXN546.26 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on AstraZeneca and its competitors. AstraZeneca's current Cyclically Adjusted Revenue per Share is MXN546.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca (MEX:AZN1N) is currently considered Fairly Valued. The stock's GF Value™ is MXN3,041.58, compared to a current price of MXN2,777.00 — trading 8.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN546.26. AstraZeneca's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For AstraZeneca (MEX:AZN1N), the current Cyclically Adjusted Revenue per Share is MXN546.26 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AstraZeneca (MEX:AZN1N) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca stock appears to be undervalued. The current stock price of MXN2,777.00 is trading 8.7% below its estimated GF Value™ of MXN3,041.58. GuruFocus considers AstraZeneca to be Fairly Valued.

Key valuation signals for MEX:AZN1N:

  • Cyclically Adjusted Revenue per Share: MXN546.26
  • GF Value™: MXN3,041.58 vs. price of MXN2,777.00 (8.7% below fair value)
  • GF Score™: 84/100 with 1 warning sign

No single metric tells the full story. See the MEX:AZN1N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AstraZeneca Business Description

Address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
84GF Score

Get the complete analysis for MEX:AZN1N

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN2,777.00
Price
MXN3,041.58
GF Value